Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors

Hims & Hers Health, Inc. (HIMS) closed at $31.65 in the latest trading session, marking a -1.59% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.17% for the day. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq depreciated by 0.83%.

Shares of the company witnessed a loss of 11.09% over the previous month, trailing the performance of the Medical sector with its loss of 2.54%, and the S&P 500's gain of 3.52%.

Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on August 10, 2026. It is anticipated that the company will report an EPS of -$0.07, marking a 141.18% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $690.21 million, up 26.68% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.27 per share and revenue of $2.91 billion, indicating changes of -150.94% and +23.78%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Hims & Hers Health, Inc. is carrying a Zacks Rank of #3 (Hold).

In the context of valuation, Hims & Hers Health, Inc. is at present trading with a Forward P/E ratio of 1206. This represents a premium compared to its industry average Forward P/E of 27.01.

One should further note that HIMS currently holds a PEG ratio of 90.51. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical Info Systems industry currently had an average PEG ratio of 3.37 as of yesterday's close.

The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 72, placing it within the top 30% of over 250 industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research